Přihlásit se Zaregistrujte se zdarma

Návratnost kapitálu společnosti Affimed N.V

Jaká je hodnota metriky Návratnost kapitálu společnosti Affimed N.V?

Hodnota metriky Návratnost kapitálu společnosti Affimed N.V. je -38.97%

Jaká je definice metriky Návratnost kapitálu?



Return on capital employed (ROCE) je finanční ukazatel, který měří rentabilitu společnosti a efektivitu společnosti ve využívání vlastního kapitálu.

Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.

ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.

Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.

Návratnost kapitálu společností v sektoru Health Care sektor na NASDAQ ve srovnání se společností Affimed N.V

Čemu se věnuje společnost Affimed N.V?

affimed (symbol: afmd) is a nasdaq-listed clinical-stage biopharmaceutical company focused on discovering and developing targeted immuno-oncology therapies. immuno-oncology represents a highly promising approach to cancer treatment that seeks to harness the body’s own immune defenses to attack and destroy tumor cells. natural killer cells, or nk-cells, and t-cells belong to the most potent cells of the human defense arsenal. affimed’s proprietary, next-generation bispecific antibodies, termed tandabs®, are designed to bring nk-cells or t-cells into close proximity to cancer cells that ultimately triggers a signal cascade that leads to the destruction of cancer cells. due to their novel tetravalent tandem architecture, which provides for four binding domains, the tandabs bind to specific targets on immune and cancer cells with high affinity. in addition, tandabs exhibit kinetic properties allowing the administration as regular intravenous infusion and fine-tuning of dosing. affimed beli

Firmy s metrikou návratnost kapitálu podobnou společnosti Affimed N.V